Landscape Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Landscape Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,299	Closed	-$345K	–	906
2023 Q4	$345K	Buy	+11,299	New	+$325K	0.03%	523
2021 Q3	–	Sell	-3,248	Closed	-$526K	–	798
2021 Q2	$526K	Buy	+3,248	New	+$253K	0.06%	261
2018 Q1	–	Sell	-46,388	Closed	-$892K	–	604
2017 Q4	$892K	Buy	46,388 +37,349	+413%	+$862K	0.08%	259
2017 Q3	$225K	Sell	9,039 -26,828	-75%	-$505K	0.02%	446
2017 Q2	$574K	Buy	+35,867	New	+$501K	0.06%	189
2016 Q3	–	Sell	-27,268	Closed	-$582K	–	544
2016 Q2	$582K	Buy	+27,268	New	+$725K	0.08%	278

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Landscape Capital Management's NTLA Position: Q1 2024 in Review

Landscape Capital Management sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 11,299 shares — an estimated $345K sold.

Landscape Capital Management first reported a position in NTLA in Q2 2016 and held it in 6 quarters. The position peaked at $892K in Q4 2017. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

Landscape Capital Management reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
Landscape Capital Management sold 11,299 Intellia Therapeutics shares in Q1 2024, an estimated $345K.
Landscape Capital Management first reported a position in Intellia Therapeutics in Q2 2016 and held it in 6 quarters.
Landscape Capital Management's Intellia Therapeutics position peaked at $892K in Q4 2017.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Landscape Capital Management's 13F filing for Q1 2024, filed 9 May 2024.